Methods and agents for improving targeting of CD138 expressing tumor cells

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9446146
APP PUB NO 20090169570A1
SERIAL NO

12342815

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BIOTEST AG;DANA-FARBER CANCER INSTITUTE, INC.;IMMUNOGEN, INC.;IMMUNOGEN, INC. (ONE-HALF INTEREST)

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Aigner, Silke Frankenthal, DE 12 163
Anderson, Kenneth Wellesley, US 44 218
Bruecher, Christoph Eschborn, DE 18 205
Daelken, Benjamin Frankfurt am Main, DE 24 227
Germer, Matthias Langen, DE 14 133
Hideshima, Teru Brookline, US 19 211
Osterroth, Frank Dietzenbach, DE 18 194
Uherek, Christoph Seligenstadt, DE 26 302

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 20, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 20, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00